REVO

- Mongolia’s National Cancer Center launches a full robotic surgery program following VR simulator-based training

- Strengthening Korea–Mongolia medical cooperation, with expectations for expanded surgical capabilities

meerecompany (CEO Joon Koo Kim) announced on the 15th that its surgical robot Revo-i has been officially installed at the National Cancer Center of Mongolia, marking the start of full-scale robotic surgery operations.

The installation follows approximately one year of preparation after meerecompany won a competitive bid from the National Cancer Center last year. As part of the preparatory phase, the company first supplied its Revo-Sim, a VR-based robotic surgery simulator, to support early-stage training for medical staff. In addition, local medical professionals visited Korea to complete structured training at meerecompany’s headquarters. With the installation of the complete Revo-i system, the project has now reached its final implementation stage.

Founded in 1961 and located in Ulaanbaatar, the National Cancer Center of Mongolia is the country’s leading national cancer specialty hospital, performing approximately 45 percent of all cancer surgeries nationwide. The center is recognized for its high-level surgical expertise, particularly in complex procedures centered on hepatobiliary and pancreatic surgery. Going forward, the hospital plans to gradually expand its robotic surgery program using Revo-i, ranging from benign disease treatment to highly complex oncologic surgeries. The center also maintains close cooperative relationships with multiple Korean medical institutions, and continued collaboration is expected in areas such as physician training and clinical exchange.

Ho Kun Lee, Executive Vice President and Head of the Surgical Robot Division at meerecompany, commented, “Following last year’s successful bid, the project has now come to fruition with the completion of simulator training and headquarters-based education. We will continue to provide training and technical support to ensure that Mongolian medical professionals can rapidly establish strong robotic surgery capabilities.”

He added, “As Revo-i’s global reference base continues to expand, trust in overseas markets is also steadily increasing. We plan to further strengthen global marketing efforts so that Revo-i can be utilized across a wider range of markets in 2026.”

Meanwhile, meerecompany has previously signed a memorandum of understanding (MOU) with the Health Development Center under Mongolia’s Ministry of Health, aimed at improving Mongolia’s healthcare system. Under the agreement, the two sides are pursuing initiatives including the additional deployment of Revo-i systems in Mongolia, the operation of robotic surgery training programs in collaboration with Korean medical institutions, and the joint hosting of seminars and academic conferences focused on advancing Mongolia’s healthcare system.